GlassScriptPhysician profile
Marlon B Ilagan
NPI 1588716492
$47,166.12
in general payments reported to CMS, 2019-2025
34 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,428 · 2020: $8,605 · 2021: $1,821 · 2022: $21K · 2023: $1,567 · 2024: $5,318 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,682 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,930.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,682.00 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21,126.82 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $15,449.28 | 2019-2023 | |
| Abbvie INC. | $4,701.42 | 2019-2025 | |
| Celgene Corporation | $1,880.45 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,016.08 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $433.88 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $382.44 | 2022-2025 | |
| Madrigal Pharmaceuticals | $303.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $289.98 | 2023-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $265.93 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.83 | 2019-2022 | |
| Pfizer INC. | $177.02 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $128.02 | 2024-2025 | Iqirvo |
| Medical Device Business Services, INC. | $116.50 | 2019 | |
| Lilly USA, LLC | $112.98 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $93.75 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $64.84 | 2019-2023 | Ocaliva |
| Novo Nordisk INC | $53.39 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $50.70 | 2024-2025 | Zenpep |
| Olympus America INC. | $45.10 | 2022-2024 | Evis Exera III Colonovideoscope |
| Romark Laboratories, Lc | $43.35 | 2019 | |
| Amgen INC. | $38.55 | 2022-2023 | Amjevita, Avsola |
| Celltrion USA INC. | $33.21 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $29.46 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $18.51 | 2021 | |
| Fresenius Kabi USA, LLC | $17.94 | 2023 | Idacio |
| Medtronic, INC. | $16.67 | 2025 | Gi Genius |
| Enterra Medical, INC. | $13.63 | 2024 | |
| Cook Medical LLC | $13.61 | 2021 | |
| Covidien LP | $12.92 | 2019 | |
| Allergan, INC. | $12.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.56 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlon Ilagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.